Home > Insider Trading > Filing (0001209191-23-043306)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1660334	Verrica Pharmaceuticals Inc.	VRCA	Pharmaceutical Preparations (2834)	463137900

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1805359	G. Christopher Hayes	C/O Verrica Pharmaceuticals Inc. 44 West Gay Street, Suite 400 West Chester PA 19380	Chief Legal Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2023-07-21	100,000	$0.00	115,714	No	4	A	Direct
Common Stock	Disposition	2023-07-24	33,789	$4.83	81,925	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	A	Direct
No	4	S	Direct

Footnotes

Represents restricted stock unit ("RSU") awards with performance based vesting, which were originally granted in 2019 and 2020. The RSUs vested 50% upon receipt of regulatory approval of the Issuer's new drug application for VP-102 for the treatment of molluscum, and the remaining 50% shallvest on July 21, 2024, subject to the Reporting Person's continuous service through each applicable date.
Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for RSUs that vested on July 21, 2023.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.75 to $4.955 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.